Hjem
Vidar M. Steens bilde

Vidar M. Steen

Professor, Professor i klinisk molekylærmedisin
  • E-postVidar.Steen@uib.no
  • Telefon+47 55 97 53 27
  • Besøksadresse
    Laboratoriebygget (6.etg.)
    Haukeland Univ.sykehus
    Rom 
    6385
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2019. Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients. European Archives of Psychiatry and Clinical Neuroscience. 1-10.
  • 2019. Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience. 1617-1623.
  • 2018. Williams Syndrome neuroanatomical score associates with GTF2IRD1 in large-scale magnetic resonance imaging cohorts: A proof of concept for multivariate endophenotypes. Translational Psychiatry. 1-8.
  • 2018. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications. 1-16.
  • 2018. Recently evolved human-specific methylated regions are enriched in schizophrenia signals. BMC Evolutionary Biology. 1-11.
  • 2018. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. Schizophrenia Research. 253-260.
  • 2018. Expression of TCN1 in Blood is Negatively Associated with Verbal Declarative Memory Performance. Scientific Reports. 1-11.
  • 2018. Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder. Translational Psychiatry. 1-10.
  • 2018. Comparison of three variant callers for human whole genome sequencing. Scientific Reports. 1-6.
  • 2018. Brain scans from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes. Molecular Psychiatry. 1-13.
  • 2018. Attenuated Notch signaling in schizophrenia and bipolar disorder. Scientific Reports. 1-8.
  • 2018. Analysis of shared heritability in common disorders of the brain. Science. 15 sider.
  • 2018. Analysis of differentially methylated regions in great apes and extinct hominids provides support for the evolutionary hypothesis of schizophrenia. Schizophrenia Research. 8 sider.
  • 2018. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome. European Journal of Human Genetics.
  • 2017. Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex. Translational Psychiatry.
  • 2017. Novel genetic loci associated with hippocampal volume. Nature Communications. 1-12.
  • 2017. Large-scale cognitive GWAS meta-analysis reveals tissue-specific neural expression and potential nootropic drug targets. Cell reports. 2597-2613.
  • 2017. Identification of gene loci that overlap between schizophrenia and educational attainment. Schizophrenia Bulletin. 654-664.
  • 2017. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report form the COGENT consortium. Molecular Psychiatry. 336-345.
  • 2017. Duplicated enhancer region increases expression of CTSB and segregates with keratolytic winter erythema in South African and Norwegian families. American Journal of Human Genetics. 737-750.
  • 2017. BRCA testing by single-molecule molecular inversion probes. Clinical Chemistry. 503-512.
  • 2017. Analysis of the joint effect of SNPs to identify independent loci and allelic heterogeneity in schizophrenia GWAS data. Translational Psychiatry.
  • 2017. A genome-wide association study of anorexia nervosa suggests a risk locus implicated in dysregulated leptin signaling. Scientific Reports. 1-9.
  • 2016. Genome-wide autozygosity is associated with lower general cognitive ability. Molecular Psychiatry. 837-843.
  • 2016. Genetics of structural connectivity and information processing in the brain. Brain Structure and Function. 4643-4661.
  • 2016. Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. European Neuropsychopharmacology. 589-598.
  • 2016. Circadian clock gene variants and insomnia, sleepiness, and shift work disorder. Sleep and Biological Rhythms. 55-62.
  • 2016. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics. 881-888.
  • 2015. Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs. Nucleic Acids Research. 3070-3081.
  • 2015. Syndromic X-linked intellectual disability segregating with a missense variant in RLIM. European Journal of Human Genetics. 1652-1656.
  • 2015. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. European Neuropsychopharmacology. 923-932.
  • 2015. MicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics.
  • 2015. Large-scale genomics unveil polygenic architecture of human cortical surface area. Nature Communications.
  • 2015. Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 363-373.
  • 2015. Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53 949). Molecular Psychiatry. 183-192.
  • 2015. Genetic basis of a cognitive complexity metric. PLOS ONE.
  • 2015. Common variants in the ARC gene are not associated with cognitive abilities. Brain and Behavior. 8 sider.
  • 2015. Common genetic variants influence human subcortical brain structures. Nature. 224-229.
  • 2015. B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. Journal of Clinical Investigation. 3051-3062.
  • 2015. Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine. Journal of Psychopharmacology. 1280-1289.
  • 2014. The ENIGMA Consortium: Large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior. 153-182.
  • 2014. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. International Journal of Neuropsychopharmacology. 91-104.
  • 2014. Molecular genetic evidence for overlap between general cognitive ability and risk for schizophrenia: A report from the Cognitive Genomics consorTium (COGENT). Molecular Psychiatry. 168-174.
  • 2014. Lack of association of the rs1344706 ZNF804A variant with cognitive functions and DTI indices of white matter microstructure in two independent healthy populations. Psychiatry Research : Neuroimaging. 60-66.
  • 2014. Genetic architecture of cognitive traits. Scandinavian Journal of Psychology. 255-262.
  • 2014. A genome-wide association study of anorexia nervosa. Molecular Psychiatry. 1085-1094.
  • 2013. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • 2013. LOC689986, a unique gene showing specific expression in restricted areas of the rodent neocortex. BMC Neuroscience. 14 sider.
  • 2013. Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of Distal Arthrogryposis. Proceedings of the National Academy of Sciences of the United States of America. 4667-4672.
  • 2013. Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition? Journal of Lipid Research.
  • 2013. A genetic deconstruction of neurocognitive traits in schizophrenia and bipolar disorder. PLOS ONE. 9 sider.
  • 2012. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. International Journal of Neuropsychopharmacology. 163-179.
  • 2012. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. PLOS ONE. 11 sider.
  • 2012. Linkage-disequilibrium-based binning affects the interpretation of GWASs. American Journal of Human Genetics. 727-733.
  • 2012. Imaging and cognitive genetics: the Norwegian Cognitive NeuroGenetics Sample. Twin Research and Human Genetics. 442-452.
  • 2012. Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics. 552-561.
  • 2012. Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma. 12 sider.
  • 2012. Genome-wide association study identifies genetic loci associated with body mass index and high density lipoprotein-cholesterol levels during psychopharmacological treatment - a cross-sectional naturalistic study. Psychiatry Research. 327-336.
  • 2012. Gene-based analysis of regionally enriched cortical genes in GWAS data sets of cognitive traits and psychiatric disorders. PLOS ONE. 14 sider.
  • 2012. DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLOS ONE. 12 sider.
  • 2012. An actigraphic validation study of seven morningness-eveningness inventories. European Psychologist. 222-230.
  • 2012. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology. 783-794.
  • 2011. The Complement Control-Related Genes CSMD1 and CSMD2 Associate to Schizophrenia. Biological Psychiatry. 35-42.
  • 2011. Olanzapine-induced hyperphagia and weight gain associate with crexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLOS ONE. 9 sider.
  • 2011. Lithium differentially affects clock gene expression in serum-shocked NIH-3T3 cells. Journal of Psychopharmacology. 924-933.
  • 2011. Lipogenic effects of psychotropic drugs: focus on the SREBP system. Frontiers in Bioscience. 49-60.
  • 2011. Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Molecular Psychiatry. 996-1005.
  • 2011. Gene expression in the rat brain: High similarity but unique differences between frontomedial-, temporal- and occipital cortex. BMC Neuroscience. 14 sider.
  • 2011. Candidate Gene Analysis of the Human Natural Killer-1 Carbohydrate Pathway and Perineuronal Nets in Schizophrenia: B3GAT2 Is Associated with Disease Risk and Cortical Surface Area. Biological Psychiatry. 90-96.
  • 2011. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry. 15-20.
  • 2011. Association study of a variable-number tandem repeat polymorphism in the clock gene PERIOD3 and chronotype in Norwegian university students. Chronobiology International. 764-770.
  • 2010. Usefulness of factor V Leiden mutation testing in clinical practice. European Journal of Human Genetics. 862-866.
  • 2010. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • 2010. Switch from stress response to homeobox transcription factors in adipose tissue after profound fat loss. PLOS ONE. 12 sider.
  • 2010. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Molecular Psychiatry. 463-472.
  • 2010. Neurogenetic effects on cognition in aging brains: A window of opportunity for intervention? Frontiers in Aging Neuroscience. 15 sider.
  • 2010. Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid Metabolism. American Journal of Human Genetics. 410-417.
  • 2010. Er formakogenetisk CYP2D6-testing nyttig? Tidsskrift for Den norske legeforening. 2224-2228.
  • 2010. Er farmakogenetisk CYP2D6-testing nyttig? Tidsskrift for Den norske legeforening. 2224-2228.
  • 2010. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 sider.
  • 2010. Association Study of PDE48 gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. American Journal of Medical Genetics. 86-96.
  • 2009. Variants in doublecortin- and calmodulin kinase like 1, a gene up-regulated by BDNF, are Associated with memory and general cognitive abilities. PLOS ONE.
  • 2009. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacology.
  • 2009. Association of MCTP2 gene variants with schizophrenia in three independent samples of Scandinavian origin (SCOPE). Psychiatry Research. 256-258.
  • 2009. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Molecular Psychiatry. 308-317.
  • 2009. An 8.9 Mb 19p13 duplication associated with precocious puberty and a sporadic 3.9 Mb 2q23.3q24.1 deletion containing NR4A2 in mentally retarded members of a family with an intrachromosomal 19p-into-19q between-arm insertion. European Journal of Human Genetics. 904-910.
  • 2009. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology. 73-84.
  • 2009. A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). Schizophrenia Research. 242-248.
  • 2008. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Molecular Psychiatry.
  • 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology. 679-684.
  • 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology. 679-684.
  • 2008. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • 2008. Auditory hallucinations in schizophrenia: the role of cognitive, brain structural and genetic disturbances in the left temporal lobe. Frontiers in Human Neuroscience. 10 sider.
  • 2008. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: pertubation of SREBP-controlled lipogenesis in drug-realted metabolic adverse effects? Molecular Psychiatry. 308-317.
  • 2008. Association Analysis of Schizophrenia on 18 Genes Involved in Neuronal Migration: MDGA1 as a New Susceptibility Gene. American Journal of Medical Genetics. 1089-1100.
  • 2008. Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development. European Journal of Human Genetics. 1318-1328.
  • 2008. A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). Schizophrenia Research.
  • 2007. Synaptic activity-induced global gene expression patterns in the dentate gyrus of adult behaving rats: Induction of immunity-linked genes. Neuroscience. 925-936.
  • 2007. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer. 10 sider.
  • 2007. Gene expression profiles in rat brain disclose CNS signature genes and regional patterns of functional specialisation. BMC Genomics.
  • 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • 2007. Associations between cod liver oil use and symptoms of depression: The Hordaland Health Study. Journal of Affective Disorders. 245-249.
  • 2007. A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • 2006. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: Relevance for metabolic side-effects? Molecular and Cellular Biochemistry. 167-173.
  • 2006. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland Health Study. Journal of Clinical Psychiatry. 1974-1982.
  • 2006. Identification of genes co-upregulated with Arc during BDNF-induced long-term potentiation in adult rat dentate gyrus in vivo. European Journal of Neuroscience. 1501-1511.
  • 2006. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. European Respiratory Journal. 682-688.
  • 2006. Farmakogenetikk og skreddersydd behandling ved schizofreni. Tidsskrift for Den norske legeforening. 2400-2402.
  • 2006. Farmakogenetikk og skreddersydd behandling ved schizofreni. Tidsskrift for Den norske legeforening. 2400-2402.
  • 2006. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: Marked differences between various antipsychotic drugs. BMC Neuroscience.
  • 2006. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neuroscience Letters. 185-190.
  • 2005. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. European Journal of Clinical Pharmacology. 499-506.
  • 2005. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. European Journal of Clinical Pharmacology. 499-506.
  • 2005. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? The Pharmacogenomics Journal. 298-304.
  • 2004. The ser9gly SNP in the dopamine D-3 receptor causes a shift from cAMP related to PGE(2) related signal transduction mechanisms in transfected CHO cells. Journal of Medical Genetics. 867-871.
  • 2004. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Molecular Psychiatry. 621-629.
  • 2004. Evaluation of five different cDNA labeling methods for microarrays using spike controls. BMC Biotechnology. 5 sider.
  • 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. Journal of Clinical Psychiatry. 1228-1234.
  • 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: Infant exposure, clinical symptoms and cytochrome P450 genotypes. Journal of Clinical Psychiatry. 1228-1234.
  • 2003. Examination of IMPA1- and IMPA2 genes in manic-depressive patients: Association between IMPA2 promoter polymorphisms and bipolar disorder. Molecular Psychiatry. Epub-23Dec2003.
  • 2003. Evaluation of of five different cDNA labeling methods for microarrays using spike controls. BMC Biotechnology.
  • 2003. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • 2003. Association between blood carisoprodol/meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: Decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • 2003. Association between blood carisoprodol/meprobamate concentration ratios and CYP2C19 genotype in carisoprodol drugged drivers: Decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • 2002. Schizofreni og molekylærgenetikk. Tidsskrift for Den norske legeforening. 2118-2122.
  • 2002. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene ser9gly polymorphism. Neuropsychopharmacology. 105-119.
  • 2002. Does inositol signalling have a role in disease susceptibility and drug treatment of bipolar disorder? Bipolar Disorders. 53-55.
  • 2001. The phospholipase C-gamma 1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatric Genetics. 41-43.
  • 2001. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Molecular Psychiatry. 6-7.
  • 2001. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics (London). 45-55.
  • 2001. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics (London). 45-55.
  • 2001. Characterization of two genes, Impa1 and Impa2 encoding mouse myo-inositol monophosphatases. Gene. 285-291.
  • 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology.
  • 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology. 61-65.
  • 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology. 61-65.
  • 2000. CYP2D6-gentest- ny rutineanalyse for identifisering av langsomme og ultraraske legemiddelomsettere. Norsk Farmaceutisk Tidsskrift. 14-15.
  • 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry.
  • 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry. 172-180.
  • 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry. 172-180.
  • 1999. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1). Pharmacogenetics (London). 517-528.
  • 1998. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illn. Pharmacogenetics (London). 259-268.
  • 1998. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illn. Pharmacogenetics (London). 259-268.
  • 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in szhizophrenic patients. Psychopharmacology. 174-179.
  • 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizofrenic patients. Psychopharmacology. 174-179.
  • 1997. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA). Genomics. 113-122.
  • 1997. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular Psychiatry. 139-145.
  • 1997. Characterization of the 16+9 kb and 30+9 kb CYP2D6 Xbal haplotypes. Pharmacogenetics (London). 149-152.
  • 1996. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters. 30-34.
  • 1996. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics (London). 113-116.
  • 1996. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics (London). 113-116.
  • 1996. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics (London). 319-328.
  • 1996. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics (London). 319-328.
  • 1996. CYP2D6 multiallelism. Methods in Enzymology. 199-210.
  • 1996. A retroviral element in the human CYP2D gene cluster. Pharmacogenetics (London). 375-377.
  • 1995. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum Molecul Genet. 2251-2257.
  • 1995. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Human Molecular Genetics. 2251-2257.
  • 1995. Detection of the poor metabolizer-associated CYP2D6(D) gene detection allele by long-PCR technology. Pharmacogenetics (London). 215-223.
  • 1995. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics (London). 215-223.
  • 1993. The platelet-stimulating effect of adrenaline through _a%c-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce platelet activation in vitro. Thrombosis and Haemostasis. 506-513.
  • 1991. Stimulation of human platelets with low concentrations of thrombin: Evidence for equimolecular formation of inositol triphosphate and phosphatidic acid. International journal of biochemistry. 305-310.
Vitenskapelig foredrag
  • 2012. Integrative genomics links homeobox transcription factors to intra-abdominal obesity.
  • 2004. Antipsychotic-induced changes in global gene expression: Demonstration of novel mechanisms of drug action based on clustering and verification of differential expressed genes.
  • 2003. Candidate genes in bipolar disorder: Implications for treatment.
  • 2001. The role of genetic variation in lithium treatment of maniac-depressive illness.
  • 2001. Inositol monophosphatase, a candidate gene for bipolar disorder?
  • 2001. IMPA1 and IMPA2 - Candidate genes for disease susceptibility and variation in drug response in lithium-treated bipolar disorder.
  • 2001. Clock genes: Regulation and gene expression.
  • 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-treated bipolar disorder.
  • 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-treated bipolar disorder.
  • 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-trated bipolar disorder.
  • 1999. Searching for genetic variations in inositol monophosphatase genes in lithium-treated manic-depressive patients.
  • 1999. Examination of a phospholipase C gamma-1 dinucleotide repeat polymorphism in Norwegian Lithium-treated bipolar patients.
  • 1999. Allele frequency and genotype distribution of a novel structural polymorphism in the alpha-2B-adrenoceptor gene in bipolar patients and normal control individuals.
  • 1999. Allele frequency and genotype distribution of a novel structural polymorphism in the (2B-adrenergic receptor in bipolar patients and normal control individuals.
  • 1999. A role of the human inositol polyphosphate 1-phosphatase gene (INPP1) in lithium-treated bipolar disorder?
  • 1998. Homozygosity for the Ser9Gly variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients: a follow-up study.
  • 1998. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1).
  • 1998. Genomic characterization of genes encoding human myo-inositol monophosphatase enzymes.
  • 1998. Gene mutations of the phosphatidylinositol signaking system in lithium-treated manic-depressive patients.
  • 1997. Screening for genetic factors which may be involved in the mechanism of action of lithium in manic depressiv illness.
  • 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • 1996. Screening for genetic fractors which may be involved in the mechanism of action lithium in manic-depressive illness.
Sammendrag/abstract
  • 2010. Genetic characterisation of PHARC - a novel syndrome resembling Refsum's disease. Neuromuscular Disorders. 680-680.
  • 2010. Gene Expression Profile of Nuclear Receptors and Coregulators in Adipose Tissues in Morbid Obesity and after Profound Fat Loss. Endocrine reviews. 1 sider.
  • 2010. From stress response to developmental processes in abdominal subcutaneous adipose tissue after bariatric surgery. Endocrine journal. S429-S429.
  • 2010. Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • 2008. Effect of clozapine on memory function in the hippocampal lesion model of schizophrenia. International Journal of Neuropsychopharmacology. 261-261.
  • 2008. Differential effects of antipsychotic drugs on ATP-binding cassette type A1 (ABCA1) and apolipoprotein E (ApoE) gene expression in cultured cells. International Journal of Neuropsychopharmacology. 259-259.
  • 2008. Antipsychotic-induced activation of cellular lipid biosynthesis: Molecular, genetic and clinical evidence for a new mechanism of metabolic drug action. International Journal of Neuropsychopharmacology. 31-31.
  • 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • 2007. Variations in side effects of antipsychotic drugs: Focus on possible mechanisms. Nordic Journal of Psychiatry. 493-493.
  • 2007. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Nordic Journal of Psychiatry. 501-501.
  • 2007. Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • 2006. Lipogenic effects of antidepressant drugs: Transcriptional stimulation of cellular lipid biosynthesis is a potential marker of drug-induced metabolic side-effects. Nordic Journal of Psychiatry. 336-336.
  • 2006. Antipsychotic and antidepressive drugs regulate the expression of apolipoprotein E. Nordic Journal of Psychiatry. 338-338.
  • 2005. Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Vitenskapelig oversiktsartikkel/review
  • 2019. Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. 1-16.

Se fullstendig oversikt over publikasjoner i CRIStin.